Nurix Therapeutics Inc (NRIX)


Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Nurix Therapeutics Inc chart...

About the Company

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe

Exchange

NASDAQ

Website

nurix-inc.com

$76M

Total Revenue

300

Employees

$716M

Market Capitalization

-5.58

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NRIX News

Nurix Therapeutics gets grant for degradation of BTK using compound of formula (a)

1d ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Nurix Therapeutics for compounds targeting and degrading BTK, offering hope for treating cancer, autoimmune diseases, and more. Explore the potential therapeutic ...

Nurix Therapeutics files patent for bifunctional compounds for hpk1 degradation in disease treatment

3d ago, source: Pharmaceutical Technology

Discover how Nurix Therapeutics' patent for bifunctional compounds targeting HPK1 activity offers a groundbreaking method for treating diseases, including cancer. Learn more about this innovative ...

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

8d ago, source:

Presentation highlights Nurix’s innovation and leadership in targeted protein modulation, including ligase inhibitionUnique mechanism of action, ...

NRIX Oct 2024 12.500 call

16d ago, source: Yahoo Finance

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

Structures of new cancer drug candidates revealed

6d ago, source: C&EN

The cancer immunotherapy talks continued with Frederick Cohen presenting NX-1607. This drug candidate was made to target CBL-B, an immune checkpoint protein that limits the ability of T cells to ...

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

8d ago, source: Zacks.com on MSN

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.18 per share a year ago. These figures are ...

New Haven-based BioXcel Therapeutics announces $25M offering

3d ago, source: Hartford Business

BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company that uses artificial intelligence to develop medicines ...

NeuBase Therapeutics sets shareholder meeting on dissolution plan

3d ago, source:

NeuBase Therapeutics will hold a special shareholder meeting May 13 to approve a plan to liquidate and dissolve the ...

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

7d ago, source:

Kymera is advancing into Phase 2 with Sanofi, which could validate protein deg approach, open up multi-billion dollar market ...

Praxis gains after mid-stage data for epilepsy candidate

on MSN ago, source:

Praxis Precision Medicines (PRAX) stock surges as its anti-seizure drug shows potential in treating epilepsy patients with photo paroxysmal response. Read more here.

Rakovina Therapeutics Announces Strategic Pivot to AI

1d ago, source:

Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...